Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
The transaction was executed at an average price of $35.19 per share, resulting in a total value of $1,407,600.Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that develops medicines to treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.Over the past year, Kenneth Myszkowski has sold a total of 71,104 shares of Arrowhead Pharmaceuticals Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 23 insider sells and no insider buys over the same timeframe. On the day of the insider's recent sale, shares of Arrowhead Pharmaceuticals Inc were trading at $35.19, giving the company a market capitalization of $4.145 billion.The stock's valuation, according to GuruFocus, indicates that Arrowhead Pharmaceuticals I
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D WebinarsBusiness Wire
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter ResultsBusiness Wire
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney DiseaseBusiness Wire
- Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses [Yahoo! Finance]Yahoo! Finance
- Leerink Taps Rothschild's Hotchandani for Health-Care Dealmaking [BNN Bloomberg (Canada)]BNN Bloomberg
ARWR
Earnings
- 8/7/23 - Miss
ARWR
Sec Filings
- 4/10/24 - Form SC
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- ARWR's page on the SEC website